Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells $358,576.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jon Coleman sold 4,912 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total transaction of $358,576.00. Following the completion of the transaction, the executive vice president directly owned 100,361 shares in the company, valued at $7,326,353. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jon Coleman also recently made the following trade(s):

• On Thursday, June 4th, Jon Coleman sold 4,911 shares of DexCom stock. The shares were sold at an average price of $74.13, for a total value of $364,052.43.

DexCom Stock Performance

NASDAQ DXCM opened at $72.86 on Monday. The company has a market cap of $28.11 billion, a PE ratio of 31.14, a price-to-earnings-growth ratio of 1.14 and a beta of 1.45. The stock’s 50 day simple moving average is $64.83 and its 200-day simple moving average is $67.04. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the company posted $0.32 EPS. The firm’s quarterly revenue was up 15.0% on a year-over-year basis. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom announced it will highlight new clinical findings, product advancements, and strategic initiatives at ADA 2026, reinforcing its case for broader CGM adoption and earlier-stage diabetes intervention. Article: Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
• Positive Sentiment: Recent commentary remained constructive, with analysts and market coverage noting DexCom’s strong Q1 momentum, global CGM growth potential, and expanding international demand, which may help support the stock. Article: Here’s Why You Should Retain DexCom Stock in Your Portfolio
• Positive Sentiment: DexCom also said it plans to acquire wellness tracking company Nutrisense and launch an enhanced Stelo app, a move that could broaden its consumer health footprint and create new engagement opportunities. Article: Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app
• Neutral Sentiment: DexCom EVP Jon Coleman sold shares in two transactions under a pre-arranged 10b5-1 plan. While the sales were disclosed as routine, insider selling can still weigh on sentiment. Article: SEC Form 4 filing
• Neutral Sentiment: Separate market commentary noted DexCom has lagged the Dow over the past year, even as analysts remain bullish on its longer-term outlook. Article: Is DexCom Stock Underperforming the Dow?

Wall Street Analyst Weigh In

DXCM has been the topic of several recent research reports. Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price on the stock in a research note on Tuesday, March 24th. Bank of America lowered their target price on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Truist Financial reaffirmed a “buy” rating and set a $80.00 target price (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Robert W. Baird set a $80.00 target price on shares of DexCom in a research note on Friday, May 1st. Finally, Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a research note on Friday, May 1st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $82.63.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Reflection Asset Management acquired a new position in shares of DexCom during the 4th quarter valued at about $25,000. Ascentis Independent Advisors acquired a new position in shares of DexCom during the 1st quarter valued at about $25,000. CVA Family Office LLC boosted its position in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares during the last quarter. MCF Advisors LLC acquired a new position in shares of DexCom during the 4th quarter valued at about $32,000. Finally, ORG Partners LLC boosted its position in shares of DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 281 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.